MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 5, 2007
Last updated: May 21, 2015
Last verified: May 2015

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition Intervention Phase
Diabetes Mellitus, Type 2
Metabolic Syndrome
Drug: MK0916
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 154
Study Start Date: August 2004
Study Completion Date: May 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have Type 2 Diabetes
  • 18 to 65 years of age

Exclusion Criteria:

  • History of Type 1 Diabetes Mellitus
  • Have been treated with insulin in the past 8 weeks
  • On a weight loss program and have ongoing weight loss
  • Taking weight loss medication
  • Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
  • Have taken another investigational drug in the last 8 weeks
  • Have active liver disease
  • Have a history of major surgery involving gastric or intestinal bypass
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00543595

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00543595     History of Changes
Other Study ID Numbers: 0916-005  2007_643 
Study First Received: October 5, 2007
Last Updated: May 21, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Metabolic Syndrome X
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Insulin Resistance
Metabolic Diseases processed this record on February 11, 2016